TransMedics Group, Inc. Share Price

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
92.08 USD +3.17% Intraday chart for TransMedics Group, Inc. +9.41% +16.66%
Sales 2024 * 367M 29.38B Sales 2025 * 490M 39.24B Capitalization 3.02B 242B
Net income 2024 * -1M -80.07M Net income 2025 * 16M 1.28B EV / Sales 2024 * 8.76 x
Net Debt 2024 * 188M 15.08B Net Debt 2025 * 205M 16.39B EV / Sales 2025 * 6.59 x
P/E ratio 2024 *
-1,299 x
P/E ratio 2025 *
206 x
Employees 584
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.17%
1 week+9.41%
Current month+24.53%
1 month+24.23%
3 months+6.51%
6 months+142.51%
Current year+16.66%
More quotes
1 week
83.13
Extreme 83.125
92.90
1 month
70.34
Extreme 70.34
97.78
Current year
69.43
Extreme 69.43
97.78
1 year
36.42
Extreme 36.4201
99.63
3 years
10.00
Extreme 10
99.63
5 years
10.00
Extreme 10
99.63
10 years
10.00
Extreme 10
99.63
More quotes
Managers TitleAgeSince
Founder 55 31/07/98
Director of Finance/CFO 56 28/02/15
Chief Tech/Sci/R&D Officer - 28/02/06
Members of the board TitleAgeSince
Chairman 79 31/12/10
Director/Board Member 67 31/12/02
Director/Board Member 68 31/12/20
More insiders
Date Price Change Volume
26/04/24 92.08 +3.17% 635,601
25/04/24 89.25 +0.42% 444,263
24/04/24 88.88 -1.90% 538,018
23/04/24 90.6 +4.73% 591,178
22/04/24 86.51 +2.79% 600,613

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
92.08 USD
Average target price
100.3 USD
Spread / Average Target
+8.96%
Consensus